Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
Is Regeneron Pharmaceuticals, Inc. (REGN) the Worst Performing Large Cap Stock to Buy According to Analysts?
We recently published a list of 10 Worst Performing Large Cap Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...
pharmaphorum4d
Regeneron and Inovio to aim immunotherapy at hard-to-treat brain tumour
Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour. Regeneron’s drug ...
pharmaphorum7d
Regeneron set for August FDA decision on BCMA bispecific
Regeneron’s bid to join the market for BCMA ... Meanwhile, additional competition could be on the way in the form of AbbVie’s ABBV-383, another BCMAxCD3 bispecific that is in a registrational ...
Yahoo Finance14d
Why Is Regeneron (REGN) Down 4.1% Since Last Earnings Report?
It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Appeals court upholds denial of Regeneron motion for injunction against Amgen
Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...